An Open-label Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban Given as a Single 80 microg/kg Bolus Plus 100 microg/kg/h Continuous Infusion for 24 Hours in Subjects With Severe Renal Impairment, and in Matched Subjects With Normal Renal Function.

Trial Profile

An Open-label Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban Given as a Single 80 microg/kg Bolus Plus 100 microg/kg/h Continuous Infusion for 24 Hours in Subjects With Severe Renal Impairment, and in Matched Subjects With Normal Renal Function.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jun 2014

At a glance

  • Drugs Otamixaban (Primary)
  • Indications Acute coronary syndromes
  • Focus Pharmacokinetics
  • Sponsors Sanofi
  • Most Recent Events

    • 05 Aug 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
    • 05 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Jan 2011 Planned End Date changed from 1 May 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top